Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Industry performance is calculated based on the previous closing price of all industry constituents
Largest Companies in This Industry
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
| 194.43 | 40.08% | | | | Buy | |
| 132.00 | 7.74% | | | | Hold | |
| 388.18 | 7.52% | | | | Buy | |
| 159.40 | 6.75% | | | | Buy | |
| 11.75 | 5.81% | | | | Hold | |
| 14.18 | 3.54% | | | | Buy | |
| 129.31 | 3.07% | | | | Strong Buy | |
| - | 2.90% | | | | — | |
| 39.57 | 2.80% | | | | Buy | |
| 88.50 | 2.38% | | | | Buy |
Investing in the Drug Manufacturers - Specialty & Generic Industry
Start Investing in Drug Manufacturers - Specialty & Generic Through These Companies
Top Performing Companies
View MoreName | Last Price | 1Y Target Est. | YTD Return |
---|---|---|---|
| - | | |
| - | | |
| 9.75 | | |
| 132.00 | | |
| 29.00 | |
High Growth Companies
View MoreName | Last Price | Growth Estimate | YTD Return |
---|---|---|---|
| | | |
| | | |
| | | |
| | | |
| | |
Drug Manufacturers - Specialty & Generic Research
View MoreDiscover the Latest Analyst and Technical Research for This Industry
Analyst Report: Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
RatingPrice TargetAnalyst Report: Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
RatingPrice TargetDaily – Vickers Top Buyers & Sellers for 05/15/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
PBH: Raising target price to $91.00
PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $91.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target